Claims

1. Use of a combination of osteopontin (OPN) and 2'-fucosyllactose (2-FL) for the preparation of a medicament in the prevention or the treatment of immunological diseases or disorders due to inflammatory factors secretion affecting a human or an animal subject, and selected from atopic dermatitis and allergy.
2. The use of a combination according to claim 1 wherein the inflammatory factor is selected from cytokines and immunoglobulins.
3. The use of a combination according to claim 2 wherein the cytokine is selected from INF-γ, IL-2, IL-4, IL-17, IL-6, IL-10, TGF-β, Tbet, GATA3 and NFκB and the immunoglobulin is selected from IgE and IgG1.
4. The use of a combination according to any of the preceding claims wherein osteopontin (OPN) is of either human or animal origin or recombinant OPN.
5. The use of a combination according to any of the preceding claims wherein 2'-fucosyllactose (2-FL) is of either natural or synthetic origin or from bacterial fermentation origin.
6. The use of a combination according to any of the preceding claims wherein the medicament using osteopontin (OPN) is to be provided to the human or animal subject in need thereof at a dosage of 2.5 to 45, preferably of 35 to 40 mg/kg body weight/day.
7. The use of a combination according to any of the preceding claims wherein the medicament using 2'-fucosyllactose (2-FL) is to be provided to the human or animal subject in need thereof at a dosage of 75 to 750, preferably of 600 mg/kg body weight/day.
8. The use of a combination according to any of the preceding claims wherein the medicament using a combination of osteopontin (OPN) and 2'-fucosyllactose (2-FL) are to be provided to the human or animal subject in need thereof in the form of one or several single unit dosage forms.
9. The use of a combination according to any of the preceding claims wherein the medicament is to be provided to the human or animal subject in need thereof when combined with or embedded in a food or nutritional or dietary supplement.